Hansson-Hedblom et al. studied cost-effectiveness in moderate to severe Crohn’s disease patients in Sweden and found out that ustekinumab is more cost-effective in the TNF-alpha-inhibitor failure population. The gene discussed is TNF; the disease is Crohn disease.